References
1. Covid C, Team R, Covid C, Team R, COVID C, Team R, et al. Coronavirus
disease 2019 in children—United States, february 12–april 2, 2020.
Morb Mortal Wkly Rep2020 ;69:422.
2. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel
coronavirus (2019-nCoV) infections among travellers from Wuhan, China,
20–28 January 2020. Eurosurveillance 2020 ;25:2000062.
3. Ashour HM, Elkhatib WF, Rahman M, Elshabrawy HA. Insights into the
recent 2019 novel coronavirus (SARS-CoV-2) in light of past human
coronavirus outbreaks. Pathogens. 2020 ;9:186.
4. Lotfi B, Farshid S, Dadashzadeh N, Valizadeh R, Rahimi MM. Is
coronavirus disease 2019 (COVID-19) associated with renal involvement? A
review of century infection. Jundishapur J Microbiol2020 ;13:1-6.
5. Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S.
Renal and liver injury following the treatment of COVID-19 by
remdesivir. J Nephropathol 2021 ;10:1-4.
6. Besharat S, Alamda NM, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar
A, et al. Clinical and demographic characteristics of patients with
covid-19 who died in modarres hospital. Open Access Maced J Med Sci2020 ;8:144-9.
7. Tabatabaii SA, Soltani P, Khanbabaee G, Sharma D, Valizadeh R,
Farahbakhsh N, et al. Sars coronavirus 2, severe acute respiratory
syndrome, and middle east respiratory syndrome in children: A review on
epidemiology, clinical presentation, and diagnosis. Arch Pediatr Infect
Dis 2020 ;8:1-8.
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020 ;395:497-506.
9. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real
estimates of mortality following COVID-19 infection. Lancet Infect
Dis2020 ;20:773.
10. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and
biochemical indexes from 2019-nCoV infected patients linked to viral
loads and lung injury. Sci China Life Sci 2020 ;63:364-74.
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological
findings of COVID-19 associated with acute respiratory distress
syndrome. Lancet Respir Med2020 ;8:420-2.
12. Meo S, Alhowikan A, Al-Khlaiwi T, Meo I, Halepoto D, Iqbal M, et al.
Novel coronavirus 2019-nCoV: prevalence, biological and clinical
characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med
Pharmacol Sci 2020 ; 24:2012-9.
13. Martin JB, Jimenez JL, Munoz-Fernandez A. Pentoxifylline and severe
acute respiratory syndrome (SARS): a drug to be considered. Med Sci
Monit 2003 ;9:SR29-SR34.
14. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung
pathology of fatal severe acute respiratory syndrome.
Lancet2003 ;361:1773-8.
15. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and
diabetes mellitus at increased risk for COVID-19 infection? Lancet
Respir Med 2020 ;8:e21.
16. Gorbalenya AE, Baker SC, Baric R, Groot RJd, Drosten C, Gulyaeva AA,
et al. Severe acute respiratory syndrome-related coronavirus: The
species and its viruses–a statement of the Coronavirus Study Group.
2020.
17. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features,
evaluation, and treatment of coronavirus (COVID-19). Statpearls
[internet]. 2022 .
18. Barzegar A, Ghadipasha M, Rezaei N, Forouzesh M, Valizadeh R. New
hope for treatment of respiratory involvement following COVID-19 by
bromhexine. Pharmacol Ther2014 ;28:98-108.
19. Brie D, Sahebkar A, Penson PE, Dinca M, Ursoniu S, Serban M-C, et
al. Effects of pentoxifylline on inflammatory markers and blood
pressure: a systematic review and meta-analysis of randomized controlled
trials. J Hypertens 2016 ;34:2318-29.
20. Torres-Alvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in
the treatment of actinic prurigo. Dermatology 2004 ;208:198-201.
21. Choonhakarn C, Chaowattanapanit S. Lipodermatosclerosis: Improvement
noted with hydroxychloroquine and pentoxifylline. J Am Acad Dermatol2012 ;66:1013-4.
22. Berman B, Wietzerbin J, Sanceau J, Merlin G, Duncan MR.
Pentoxifylline inhibits certain constitutive and tumor necrosis
factor-α-induced activities of human normal dermal fibroblasts. J Invest
Dermatol1992 ;98:706-12.
23. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study
of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A
possible reason underlying different outcome between sex. J Med
Virol2020 ;92:2050-4.
24. Wray S, Arrowsmith S. The Physiological Mechanisms of the Sex-Based
Difference in Outcomes of COVID19 Infection. Front Physiol2021 ;12:627260.
25. Feily A, Daneshpay K, Alighadr A. COVID-19: Pentoxifylline as a
potential adjuvant treatment. Int J Clin Pharmacol
Ther2020 ;58:406-7.
26. Gonzalez-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza A.
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase
inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and
anti-fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev Med
Pharmacol Sci 2020 ;24:7494-6.
27. Hendry BM, Stafford N, Arnold AD, Sangwaiya A, Manglam V, Rosen SD,
et al. Hypothesis: Pentoxifylline is a potential cytokine modulator
therapeutic in COVID-19 patients. Pharmacol Res Perspect2020 ;8:e00631.
28. Maldonado V, Hernandez-Ramirez C, Oliva-Perez EA, Sanchez-Martinez
CO, Pimentel-Gonzalez JF, Molina-Sanchez JR, et al. Pentoxifylline
decreases serum LDH levels and increases lymphocyte count in COVID-19
patients: Results from an external pilot study. Int Immunopharmacol2021 ;90:107209.
29. Frampton JE, Brogden RN. Pentoxifylline (Oxpentifylline). Drugs
Aging. 1995 ;7:480-503.
30. Frost ML, Treadwell P. Treatment of sickle cell leg ulcers with
pentoxifylline. Int J Dermatol 1990 ;29:375-6.
31. Feret W, Nalewajska M, Wojczynski L, Witkiewicz W, Klos P,
Dziedziejko V, et al. Pentoxifylline as a Potential Adjuvant Therapy for
COVID-19: Impeding the Burden of the Cytokine Storm. J Clin
Med2021 ;10.
32. Ghasemnejad-Berenji M, Pashapour S, Sadeghpour S. Pentoxifylline: A
Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in
the Treatment of Coronavirus Disease 2019. Med Princ Pract2021 ;30:98-100.
33. Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A,
Hanifiha M, Goodarzi A. Treatment of COVID-19 with pentoxifylline: Could
it be a potential adjuvant therapy? Dermatol Ther2020 ;33:e13733.
34. Monji F, Al-Mahmood Siddiquee A, Hashemian F. Can pentoxifylline and
similar xanthine derivatives find a niche in COVID-19 therapeutic
strategies? A ray of hope in the midst of the pandemic. Eur J Pharmacol2020 ;887:173561.
35. Collado-Chagoya R, Hernandez-Chavero H, Ordinola Navarro A,
Castillo-Castillo D, Quiroz-Melendez JG, Gonzalez-Veyrand E, et al. CT
findings in survivors and non-survivors of COVID-19 and clinical
usefulness of a CT scoring system. Radiologia (Engl Ed)2022 ;64:11-6.
36. Kurzeder L, Jorres RA, Unterweger T, Essmann J, Alter P, Kahnert K,
et al. A simple risk score for mortality including the PCR Ct value upon
admission in patients hospitalized due to COVID-19. Infection.2022 .
37. Boehme AK, Doyle K, Thakur KT, Roh D, Park S, Agarwal S, et al.
Disorders of Consciousness in Hospitalized Patients with COVID-19: The
Role of the Systemic Inflammatory Response Syndrome. Neurocrit
Care2022 ;36:89-96.
38. Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E,
et al. Impact of chronic liver disease upon admission on COVID-19
in-hospital mortality: Findings from COVOCA study. PLOS ONE2020 ;15:e0243700.
39. Tian ML, Shen Y, Sun ZL, Zha Y. Efficacy and safety of combining
pentoxifylline with angiotensin-converting enzyme inhibitor or
angiotensin II receptor blocker in diabetic nephropathy: a
meta-analysis. Int Urol Nephrol 2015 ;47:815-22.
40. Schüller SS, Kempf K, Unterasinger L, Strunk T, Berger A.
Intravenous pentoxifylline is well tolerated in critically ill preterm
infants with sepsis or necrotizing enterocolitis. Eur J Pediatr2020 ;179:1325-30.
41. Sun S-Y, Li Y, Gao Y-Y, Ran X-W. Efficacy and Safety of
Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis. Int J
Low Extrem Wounds2021 ;15347346211050769.
42. Dadashzadeh N, Farshid S, Valizadeh R, Nanbakhsh M, Mohammad Rahimi
M. Acute respiratory distress syndrome in COVID-19. Immunopathol Persa.2020 ;6:e16.
43. Daneshfar M, Dadashzadeh N, Ahmadpour M, Ragati Haghi H, Rahmani V,
Frouzesh M, et al. Lessons of mortality following COVID-19 epidemic in
the United States especially in the geriatrics. J Nephropharmacol.2021 ;10:e06.
44. Besharat S AN, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar A,
Tavana S, et al. Clinical and demographic characteristics of patients
with COVID-19 who died in Modarres hospital. Open Access Maced J Med
Sci. 2020 ;8:144-9.
45. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K,
Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm
and AstraZeneca vaccines to stop COVID-19; a review and discussion.
Immunopathol Persa. 2021 ;7:e31.